TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36167851
Drug: Opt-out protocol
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Opt-out protocol for antibiotic de-escalation
Study: 33078727
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg and amoxicillin 1 g bid during the early half of treatment, followed by esomeprazole 40 mg with levofloxacin 500 mg and tinidazole 500 mg bid during the second half of treatment (Group A)
Study: 33078727
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg and amoxicillin 1 g bid during the early half of treatment, followed by esomeprazole 40 mg with clarithromycin 500 mg bid during the second half of treatment (Group B)
Study: 34369902
Drug: olanzapine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: olanzapine (10 mg) + placebo
Study: 34369902
Drug: olanzapine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: olanzapine (10 mg) + miricorilant (600 mg)
Study: 33125405
Drug: Intraoperative substitution
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative substitution of volume and other co-medications
Study: 33911859
Drug: Ensifentrine 0.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensifentrine 0.375 mg + tiotropium
Study: 32306982
Drug: Routine Veterans
Normalized name: benzalkonium chloride Topical Foam [Veteran Shield 24]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine Veterans Health Administration (VHA) primary care
Study: 34890830
Drug: Surface treatment
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surface treatment of materials
Study: 615918851
Drug: Dexamethasone intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone intravitreal implant (Ozurdex)
Study: 34871104
Drug: hu14.18K322A with
Approvals — FDA: no, EMA: no, PMDA: no
Description: hu14.18K322A with induction chemotherapy
Study: 36335783
Drug: Regorafenib 120
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 120 mg QD (arm B)
Study: 36335783
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg QD 1 week on/1 week off (arm C)
Study: 32668474
Drug: Radiotherapy (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy (median dose of 59.4Gy within 2 months after ESD)
Study: 34379996
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (maintained usual activities of daily living)
Study: 32766779
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (3 sessions of physical therapy including desensitization maneuvers and tendon/nerve gliding exercise program)
Study: 33572618
Drug: Early physiotherapy
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early physiotherapy program (functional exercises, scar manual therapy, educational tips)
Study: 33740922
Drug: Equine-Assisted Activities
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equine-Assisted Activities (EAA), 40-minute sessions twice a week for 16 weeks.
Study: 33740922
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (daily life without special treatments).
Study: 32605909
Drug: Standard-dose pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose pembrolizumab (2 mg/kg amended to 200 mg) plus reduced-dose ipilimumab (1 mg/kg) every 3 weeks for four cycles, then pembrolizumab alone for up to 2 years
Study: 32535646
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg intravenous adrenaline
Study: 35126620
Drug: Shuangshen Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuangshen Decoction combined with immunological preparations
Study: 35126620
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment and immune agents (routine group)
Study: 33626166
Drug: Prompt treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt treatment (≤ 6 days)
Study: 33626166
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (> 10 days)
Study: 33646447
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral steroid dose of >10 mg
Study: 33646447
Drug: Other immunosuppressants
Normalized name: Other immunosuppressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other immunosuppressants (injected steroids, cyclophosphamide, biological agents, methotrexate, cyclosporine)
Study: 32720384
Drug: High-dose omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose omega-3 icosapent ethyl
Study: 98327681
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral tolcapone
Study: 98327681
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg intravenous tolcapone
Study: 36284318
Drug: Dabigatran (110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran (110 or 150 mg twice daily)
Study: 33693475
Drug: Adaptive designs,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive designs, master protocols, drug repurposing, in silico trials, N-of-1 trials
Study: 32860005
Drug: Forsythin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forsythin (single oral administration)
Study: 37741105
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonists
Study: 34936232
Drug: Hydrocodone/acetaminophen (APAP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone/acetaminophen (APAP)
Study: 34842189
Drug: Oral type
Normalized name: adenovirus vaccine live oral type-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral type 1 IFN
Study: 36256646
Drug: unadjuvanted vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: unadjuvanted vaccine 15μg H7N9
Study: 34609452
Drug: Subcutaneous scopolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous scopolamine butylbromide
Study: 39025785
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg
Study: 39025785
Drug: Ticagrelor 60
Normalized name: ticagrelor 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 60 mg
Study: 35852024
Drug: Smaller glasses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smaller glasses (290 ml)
Study: 35852024
Drug: Larger glasses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larger glasses (370 ml)
Study: 34391263
Drug: Finding-oriented manual
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finding-oriented manual therapy techniques (MTT), 9 treatments over a three-week period
Study: 35945582
Drug: Online self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Online self-help intervention based on Acceptance and Commitment Therapy (ACT) for 8 weeks with therapeutic email guidance
Study: 32345348
Drug: Intense regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intense regimen of 12-h IO-therapy per day for 4 weeks
Study: 32345348
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen of 4-h IO-therapy per day for 12 weeks
Study: 35524938
Drug: Buprenorphine buccal
Normalized name: buprenorphine Buccal Film
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine buccal film (BBF) 900 µg
Study: 34587383
Drug: REGEN-COV 2400-mg
Normalized name: casirivimab
DrugBank: Casirivimab (DB15941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: REGEN-COV 2400-mg and 1200-mg
Study: 34587383
Drug: REGEN-COV 2400-mg
Normalized name: casirivimab
DrugBank: Casirivimab (DB15941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: REGEN-COV 2400-mg
Study: 34819266
Drug: Durvalumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab + chemotherapy (platinum-based, ≤4 cycles) prior to surgery, followed by durvalumab monotherapy (q4w, for an additional 12 cycles post surgery)
Study: 34819266
Drug: Durvalumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab + chemotherapy
Study: 38227033
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + chemotherapy
Study: 32520820
Drug: Hybrid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid treatment
Study: 33530511
Drug: Calcifediol weekly
Normalized name: Calcifediol
DrugBank: Calcifediol (DB00146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcifediol weekly oral dose
Study: 33530511
Drug: Weekly cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly cholecalciferol
Study: 39668137
Drug: Olaparib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (300 mg twice daily)
Study: 32565595
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g hydroalcoholic extract of Fenugreek seeds daily for 3 months
Study: 33630646
Drug: CDP-Choline 500
Normalized name: CDP-choline
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP-Choline 500 mg
Study: 33630646
Drug: CDP-Choline 1000
Normalized name: CDP-choline
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP-Choline 1000 mg
Study: 33630646
Drug: CDP-Choline 2000
Normalized name: CDP-choline
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP-Choline 2000 mg
Study: 32000790
Drug: Arm-specific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm-specific treatment delivered by a physiotherapist (Control Group)
Study: 36244828
Drug: Pattern of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pattern of CA-125 change following chemotherapy cycle 1
Study: 36068494
Drug: eptinezumab 100
Normalized name: EPTINEZUMAB 100 mg in 1 mL INTRAVENOUS INJECTION [Vyepti]
Approvals — FDA: no, EMA: no, PMDA: no
Description: eptinezumab 100 mg or 300 mg, administered intravenously once every 12 weeks for up to two doses
Study: 33961539
Drug: Message recommending
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Message recommending fewer doses at age 11–12
Study: 33961539
Drug: Message recommending
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Message recommending fewer doses before age 15
Study: 36343030
Drug: Intravascular irradiation
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravascular irradiation of blood (ILIB) combined with myofunctional exercises; active application of ILIB performed twice a week for 8 weeks.
Study: 36343030
Drug: Placebo ILIB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ILIB combined with myofunctional exercises; application of placebo ILIB and an orofacial myofunctional therapy (MFT) exercise protocol.
Study: 32673619
Drug: therapy with
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: therapy with retreat possibility with conspecifics
Study: 32673619
Drug: therapy with
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: therapy with retreat possibility without conspecifics
Study: 32673619
Drug: therapy without
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: therapy without retreat possibility
Study: 33711782
Drug: pooled-dose MF/IND
Approvals — FDA: no, EMA: no, PMDA: no
Description: pooled-dose MF/IND
Study: 33711782
Drug: pooled-dose MF
Normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pooled-dose MF
Study: 33711782
Drug: pooled-dose MF/IND/GLY
Approvals — FDA: no, EMA: no, PMDA: no
Description: pooled-dose MF/IND/GLY
Study: 33711782
Drug: medium-dose MF/IND
Approvals — FDA: no, EMA: no, PMDA: no
Description: medium-dose MF/IND
Study: 33711782
Drug: high-dose MF/IND/GLY
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose MF/IND/GLY
Study: 32862676
Drug: Control -
Normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control - two doses of 50 ml 0.9% saline IV
Study: 35293030
Drug: apalutamide 240
Normalized name: apalutamide 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: apalutamide 240 mg
Study: 35129040
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg LN18178
Study: 35129040
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg LN18178
Study: 35025025
Drug: Cefiderocol 2
Normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cefiderocol 2 g, 3-h infusion, q8h for 7-14 days
Study: 35317821
Drug: Flexible low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Flexible low-dose antagonist (0.25 mg every other day, adjusted to 0.25 mg daily based on LH levels)
Study: 35317821
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose antagonist
Study: 33356418
Drug: Four courses
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four courses of chemotherapy (including high-dose Ara-C)
Study: 33356418
Drug: Three courses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three courses of chemotherapy
Study: 36215323
Drug: Monthly dihydroartemisinin‐piperaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly dihydroartemisinin‐piperaquine (DP)
Study: 32350175
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of L-carnitine (LC)
Study: 32350175
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of L-carnitine (LC) + 30 mg of CoQ10
Study: 33151597
Drug: Conventional non-GLP-1-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional non-GLP-1-based therapy
Study: 35577602
Drug: 15 U
Normalized name: vitamin E 15 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 U Ultra Rapid Lispro (URLi) administered subcutaneously into the upper arm
Study: 35577602
Drug: 15 U
Normalized name: vitamin E 15 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 U Ultra Rapid Lispro (URLi) administered subcutaneously into the thigh
Study: 35577602
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) bolus administration of Ultra Rapid Lispro (URLi)
Study: 32896294
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (1000 mg ferric carboxymaltose in 100 mL normal saline, infusion over 15 min)
Study: 32896294
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 mL normal saline, infusion over 15 min)
Study: 38296290
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron
Study: 35939921
Drug: Oral antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antipsychotics (OAPs)
Study: 32511682
Drug: Antibiotic prescribing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prescribing at visits that met criteria (205 out of 214 visits, 96%)
Study: 32511682
Drug: Antibiotic prescribing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prescribing at visits that did not meet criteria (193 out of 211 visits, 92%)
Study: 35040920
Drug: 5-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day antibiotic treatment
Study: 35040920
Drug: 10-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day antibiotic treatment
Study: 36067389
Drug: Health problem
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health problem (e.g., hypertension)
Study: 36067389
Drug: Healthy state
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy state (e.g., normal blood pressure)
Study: 33941098
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 ?g/kg) for 10 min before surgery infusion (Group D)
Study: 33941098
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion for 10 min before surgery (Group S)
Study: 35550679
Drug: 2000 IU
Normalized name: D 2000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 IU daily vitamin D3 for 12 weeks
Study: 35550679
Drug: 60,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60,000 IU weekly for 3 weeks
Study: 35550679
Drug: 60,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60,000 IU weekly for 6 weeks
Study: 35322981
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (5 mL)
Study: 35176844
Drug: Sinecatechins 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinecatechins 10% ointment applied 3 times daily for 4 months after cryotherapy
Study: 33895598
Drug: Welcome Basket
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Welcome Basket peer support intervention (1–2 sessions pre-discharge and weekly for a month post-discharge)
Study: 34448177
Drug: Educational program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational program (4 sessions at weekly intervals)
Study: 37417644
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (Stratacel silicone gel)
Study: 33413702
Drug: Low RF
Normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low RF (300 mg)
Study: 33413702
Drug: Medium RF
Normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium RF (600 mg)
Study: 32449530
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily for 6 weeks)
Study: 35199165
Drug: gD‐2 HSV
Approvals — FDA: no, EMA: no, PMDA: no
Description: gD‐2 HSV vaccine adjuvanted with ASO4
Study: 35199165
Drug: Neutralizing antibodies
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralizing antibodies to HSV-1
Study: 35199165
Drug: Neutralizing antibodies
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralizing antibodies to HSV-2
Study: 35869682
Drug: TCI started
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TCI started with TBC set at 2.2 μg/ml
Study: 35869682
Drug: TCI started
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TCI started with TBC set at 2.6 μg/ml
Study: 33430924
Drug: Placebo 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 350 mg b.i.d.
Study: 34247392
Drug: Dopaminergic antagonist
Normalized name: Dopaminergic antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic antagonist
Study: 35422003
Drug: Peer-supported instant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer-supported instant messaging service (IMS) intervention in addition to standard diabetes therapy for 7 months
Study: 35422003
Drug: Standard diabetes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diabetes therapy
Study: 36057629
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without added supplementation.
Study: 36057629
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with 250 ml fruit smoothie.
Study: 35253334
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg/day
Study: 33569732
Drug: Se‐NP (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Se‐NP (1 mg/kg diet)
Study: 33569732
Drug: Se/Zn‐NP (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Se/Zn‐NP (1 mg/kg Se‐NP and 10 mg/kg Zn‐NP)
Study: 33052762
Drug: Mindfulness-Informed Intervention
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindfulness-Informed Intervention (MII) consisting of mindfulness training with cognitive, behavioral, and psychoeducational components, delivered in four 2-hour sessions weekly
Study: 32585738
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day milnacipran
Study: 34709582
Drug: Metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1000 mg
Study: 36254907
Drug: Nebulized normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized normal saline (NS) along with intravenous (IV) antibiotics
Study: 35421369
Drug: Nintedanib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib (150 mg or 200 mg twice daily for 12 weeks)
Study: 35970518
Drug: UMEC/VI 62.5/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC/VI 62.5/25 μg
Study: 35245227
Drug: Frankincense essential
Normalized name: FRANKINCENSE 30 g in 30 mL TOPICAL OIL [Frankincense Essential]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frankincense essential oil applied to the soles of the feet twice a day for 2 days before, during, and 2 days after chemotherapy.
Study: 36411403
Drug: MomsTalkShots (educational
Approvals — FDA: no, EMA: no, PMDA: no
Description: MomsTalkShots (educational videos tailored to vaccine intentions, attitudes, and demographics)
Study: 33403525
Drug: Partial/complete response
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial/complete response of distant disease to chemotherapy
Study: 36919444
Drug: Active repetitive
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active repetitive transcranial magnetic stimulation treatment for 4 weeks
Study: 34490741
Drug: GIP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIP infusion (4 pmol/kg/min)
Study: 39557109
Drug: Warfarin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin + placebo
Study: 32567234
Drug: NPWT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPWT with instillation of polyhexamethylene biguanide solution
Study: 32567234
Drug: Standard NPWT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard NPWT without instillation therapy